Vascular Endothelial Growth Factor A
-
Subject Areas on Research
-
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
-
3D Culture Facilitates VEGF-Stimulated Endothelial Differentiation of Adipose-Derived Stem Cells.
-
A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
-
A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
-
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
-
A VEGF trap inhibits the beneficial effect of bFGF on vasoreactivity in corporal tissues of hypercholesterolemic rabbits.
-
A centrifugal fluidic immunoassay for ocular diagnostics with an enzymatically hydrolyzed fluorogenic substrate.
-
A dynamic H3K27ac signature identifies VEGFA-stimulated endothelial enhancers and requires EP300 activity.
-
A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
-
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
-
A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy.
-
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
-
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
-
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
-
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.
-
Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor.
-
Abl family kinases regulate endothelial barrier function in vitro and in mice.
-
Acidic stress promotes a glioma stem cell phenotype.
-
Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo.
-
Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells.
-
Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
-
Acute local subcutaneous VEGF165 injection for augmentation of skin flap viability: efficacy and mechanism.
-
Adaptive mechanisms that preserve cardiac function in mice without myoglobin.
-
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
-
Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.
-
Adrb2 controls glucose homeostasis by developmental regulation of pancreatic islet vasculature.
-
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
-
Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.
-
Age-related macular degeneration.
-
Age-related macular degeneration: why should stroke physicians care?
-
Aged human muscle demonstrates an altered gene expression profile consistent with an impaired response to exercise.
-
Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia.
-
Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema.
-
Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.
-
Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence.
-
Ameroid constrictor versus hydraulic occluder: creation of hibernating myocardium.
-
An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.
-
An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis.
-
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
-
An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia.
-
An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.
-
An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone.
-
Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations.
-
Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models.
-
Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells
-
Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium.
-
Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
-
Angiogenesis-like activity of endothelial cells co-cultured with VEGF-producing smooth muscle cells.
-
Angiogenesis: an adaptive dynamic biological patterning problem.
-
Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury.
-
Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia.
-
Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes.
-
Angiotensin II promotes development of the renal microcirculation through AT1 receptors.
-
Anti-VEGF therapies in the clinic.
-
Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
-
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
-
Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy.
-
Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion.
-
Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
-
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.
-
Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct.
-
Anti-angiogenic therapy in renal cell cancer.
-
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
-
Antibody-targeted photodynamic therapy.
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
-
Apolipoprotein E Mimetic Peptide Increases Cerebral Glucose Uptake by Reducing Blood-Brain Barrier Disruption after Controlled Cortical Impact in Mice: An 18F-Fluorodeoxyglucose PET/CT Study.
-
Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration.
-
Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
-
Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways.
-
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
-
Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).
-
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.
-
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
-
Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).
-
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
-
Association of Pediatric Choroidal Neovascular Membranes at the Temporal Edge of Optic Nerve and Retinochoroidal Coloboma.
-
Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.
-
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.
-
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
-
Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
-
Best practices for treatment of retinal vein occlusion.
-
Bevacizumab and everolimus in renal cancer: a rational way forward.
-
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
-
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
-
Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.
-
Bevacizumab for retinopathy of prematurity.
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
-
Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.
-
Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy.
-
Biological basis of bone formation, remodeling, and repair-part I: biochemical signaling molecules.
-
Biomarkers for Nonexudative Age-Related Macular Degeneration and Relevance for Clinical Trials: A Systematic Review.
-
Biomarkers of response and resistance to antiangiogenic therapy.
-
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
-
Branching out: origins of the sea urchin larval skeleton in development and evolution.
-
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
-
COMPARISON OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHIC CHANGES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ALONE OR IN COMBINATION WITH PHOTODYNAMIC THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY.
-
CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
-
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
-
Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
-
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
-
Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.
-
Cardiac myocyte p38α kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart.
-
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
-
Cell-Demanded VEGF Release via Nanocapsules Elicits Different Receptor Activation Dynamics and Enhanced Angiogenesis
-
Cellular microRNAs correlate with clinical parameters in multiple injury patients.
-
Change in surface roughness by dynamic shape-memory acrylate networks enhances osteoblast differentiation.
-
Change in vision-related quality of life and influencing factors in Asians receiving treatment for neovascular age-related macular degeneration.
-
Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials.
-
Chemically Orthogonal Protein Ligation Domains for Independent Control of Hydrogel Modification with Adhesive Ligands and Growth Factors.
-
Cholesterol feeding reduces vascular endothelial growth factor signaling in rabbit corporal tissues.
-
Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
-
Ciliogenesis mechanisms mediated by PAK2-ARL13B signaling in brain endothelial cells is responsible for vascular stability.
-
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
-
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
-
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.
-
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
-
Clinical practice. Retinal-vein occlusion.
-
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
-
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
-
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
-
Combination therapy for macular edema secondary to retinal vein occlusion.
-
Combinations of Bevacizumab With Cancer Immunotherapy.
-
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
-
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
-
Combined-modality therapy for rectal cancer: future prospects.
-
Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury.
-
Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
-
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
-
Comparison of Visual Outcomes in Coats' Disease: A 20-Year Experience.
-
Complementary Approaches for Military Women with Chronic Pelvic Pain: A Randomized Trial.
-
Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization.
-
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport.
-
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
-
Controlled Protein Delivery Based on Enzyme-Responsive Nanocapsules
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
-
Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
-
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
-
Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008.
-
Coupled myovascular expansion directs cardiac growth and regeneration.
-
Covalently-immobilized vascular endothelial growth factor promotes endothelial cell tubulogenesis in poly(ethylene glycol) diacrylate hydrogels.
-
Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro.
-
Current and Emerging Treatment for Diabetic Macular Edema.
-
Current insights on the biology and clinical aspects of VEGF regulation.
-
Current management of diabetic tractional retinal detachments.
-
Cutaneous lesions of secondary syphilis are highly angiogenic.
-
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.
-
Delayed administration of recombinant human parathyroid hormone improves early biomechanical strength in a rat rotator cuff repair model.
-
Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
-
Diabetic macular edema: Evidence-based management.
-
Diabetic retinopathy.
-
Differences in Presentation and Outcomes in Males and Females With Branch Retinal Vein Occlusion.
-
Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells.
-
Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
-
Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion.
-
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
-
Differential expression of VEGF isoforms in mouse during development and in the adult.
-
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
-
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.
-
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
-
Direct myocardial revascularization and angiogenesis--how many patients might be eligible?
-
Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections.
-
Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT.
-
Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling.
-
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
-
Dual-function injectable angiogenic biomaterial for the repair of brain tissue following stroke.
-
Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism.
-
Early wound healing exhibits cytokine surge without evidence of hypoxia.
-
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
-
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
-
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
-
Effect of Prior Anti-VEGF Injections on the Risk of Retained Lens Fragments and Endophthalmitis after Cataract Surgery in the Elderly.
-
Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
-
Effect of host microenvironment on the microcirculation of human colon adenocarcinoma.
-
Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165).
-
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.
-
Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.
-
Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.
-
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
-
Efficacy and mechanism of adenovirus-mediated VEGF-165 gene therapy for augmentation of skin flap viability.
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
-
Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia.
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
-
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
-
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
-
Electrical stimulation directly induces pre-angiogenic responses in vascular endothelial cells by signaling through VEGF receptors.
-
Emerging therapeutic approaches in the management of retinal angiogenesis and edema.
-
Endogenous S-nitrosothiols protect against myocardial injury.
-
Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
-
Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.
-
Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.
-
Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia.
-
Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes
-
Enzyme-Responsive Delivery of Multiple Proteins with Spatiotemporal Control
-
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
-
Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.
-
Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells.
-
Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.
-
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).
-
Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement.
-
Evolving revascularization approaches for myocardial ischemia.
-
Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.
-
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
-
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
-
Eyes With Acute, Treatment-Naïve CRVO and Foveal Intraretinal Hemorrhage: Characteristics and Outcomes.
-
FAK/Src family of kinases: protective or aggravating factor for ischemia reperfusion injury in nervous system?
-
First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
-
Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
-
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
-
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.
-
Fluvastatin downregulates VEGF-A expression in TNF-α-induced retinal vessel tortuosity.
-
Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema.
-
Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6.
-
Functional computed tomography imaging of tumor-induced angiogenesis: preliminary results of new tracer kinetic modeling using a computer discretization approach.
-
Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics.
-
Gene therapy: role in myocardial protection.
-
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
-
Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?
-
Genetic variation determines VEGF-A plasma levels in cancer patients.
-
Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.
-
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
-
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
-
HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity.
-
HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors.
-
HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
-
Healing of a free tracheal autograft is enhanced by topical vascular endothelial growth factor in an experimental rabbit model.
-
Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity.
-
Human umbilical cord blood endothelial progenitor cells decrease vein graft neointimal hyperplasia in SCID mice.
-
Hyaluronic acid and fibrin hydrogels with concentrated DNA/PEI polyplexes for local gene delivery
-
Hypoxia, angiogenesis, and lung cancer.
-
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
-
Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.
-
Hypoxic Gene Expression of Donor Bronchi Linked to Airway Complications after Lung Transplantation.
-
IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
-
IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors.
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
-
Immunohistochemical identification of vascular endothelial growth factor in pig latissimus dorsi musculocutaneous flaps following ischemia-reperfusion injury.
-
Immunological Aspects of Age-Related Macular Degeneration.
-
Impact and Implication of Fovea-Involving Intraretinal Hemorrhage after Acute Branch Retinal Vein Occlusion.
-
Impact of Baseline Quantitative OCT Features on Response to Risuteganib for the Treatment of Dry Age-Related Macular Degeneration: The Importance of Outer Retinal Integrity.
-
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
-
Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
-
Implications of Increase in Vascular Permeability in Tumors by VEGF: A Commentary on the Pioneering Work of Harold Dvorak.
-
Improved Angiogenesis in Response to Localized Delivery of Macrophage-Recruiting Molecules.
-
Improving Outcomes for Patients With Diabetic Macular Edema.
-
In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia.
-
In vitro characterization of vascular endothelial growth factor and dexamethasone releasing hydrogels for implantable probe coatings.
-
Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
-
Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy.
-
Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections.
-
Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities.
-
Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.
-
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
-
Induction and maintenance of increased VEGF protein by chronic motor nerve stimulation in skeletal muscle.
-
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
-
Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis.
-
Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
-
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.
-
Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration.
-
Interception of host angiogenic signalling limits mycobacterial growth.
-
Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
-
Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
-
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
-
Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
-
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
-
Intravitreal aflibercept for diabetic macular edema.
-
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
-
Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
-
Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.
-
Is This a 737 Max Moment for Brolucizumab?
-
Large-scale death of retinal astrocytes during normal development is non-apoptotic and implemented by microglia.
-
Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration.
-
Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.
-
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Long- and short-term effects of biological hydrogels on capsule microvascular density around implants in rats.
-
Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.
-
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
-
Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
-
Lower capillarization, VEGF protein, and VEGF mRNA response to acute exercise in the vastus lateralis muscle of aged vs. young women.
-
Macrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularization.
-
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
-
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
-
Mast cells contribute to Enterovirus 71 infection-induced pulmonary edema in neonatal mice.
-
Mechanisms of action of rapamycin in gliomas.
-
Medicare costs for neovascular age-related macular degeneration, 1994-2007.
-
Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
-
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
-
Micron-scale spatially patterned, covalently immobilized vascular endothelial growth factor on hydrogels accelerates endothelial tubulogenesis and increases cellular angiogenic responses.
-
Molecular markers for incidence, prognosis, and response to therapy.
-
Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?
-
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
-
Multiple etiologies of tumor hypoxia require multifaceted solutions.
-
Myopic choroidal neovascularisation: current concepts and update on clinical management.
-
NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment.
-
NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.
-
New treatment approaches for osteonecrosis of the femoral head: an overview.
-
Nicotine increases size and severity of experimental choroidal neovascularization.
-
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
-
Novel antiangiogenic therapies for renal cell cancer.
-
OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study.
-
Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation.
-
Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications.
-
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
-
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.
-
Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Optimal weight in estimating and comparing areas under the receiver operating characteristic curve using longitudinal data.
-
Osteopontin expression and adventitial angiogenesis induced by local vascular endothelial growth factor 165 reduces experimental aortic calcification.
-
Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
-
Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
-
Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
-
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
-
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.
-
PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial.
-
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
-
PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
-
PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects.
-
Palmitoyl acyltransferase, Zdhhc13, facilitates bone mass acquisition by regulating postnatal epiphyseal development and endochondral ossification: a mouse model.
-
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
-
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
-
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.
-
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
-
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
-
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
-
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
-
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
-
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors.
-
Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery.
-
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
-
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
-
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
-
Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
-
Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression.
-
Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity.
-
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.
-
Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
-
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
-
Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.
-
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).
-
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
-
Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer.
-
Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy.
-
Porous hyaluronic acid hydrogels for localized nonviral DNA delivery in a diabetic wound healing model
-
Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage.
-
Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.
-
Prediction of venous thromboembolism using clinical and serum biomarker data from a military cohort of trauma patients.
-
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance.
-
Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines.
-
Prevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab.
-
Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.
-
Prognostic marker analysis in pediatric intracranial ependymomas.
-
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
-
Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
-
Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
-
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
-
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
-
Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
-
Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment.
-
Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.
-
RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
-
ROS production and angiogenic regulation by macrophages in response to heat therapy.
-
Radiation-induced hypoxia may perpetuate late normal tissue injury.
-
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
-
Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.
-
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
-
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
-
Ranibizumab for neovascular age-related macular degeneration.
-
Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
-
Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE.
-
Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay.
-
Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography.
-
Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.
-
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.
-
Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
-
Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor.
-
Reduction of Stat3 activity attenuates HIV-induced kidney injury.
-
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
-
Regulation of endothelial cell activation and angiogenesis by injectable peptide nanofibers.
-
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells.
-
Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes.
-
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.
-
Relationship of smoking and fibrosis in patients with chronic hepatitis C.
-
Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.
-
Reply.
-
Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to Aflibercept.
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
-
Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival.
-
Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
-
Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor.
-
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
-
Role of deformable cancer cells on wall shear stress-associated-VEGF secretion by endothelium in microvasculature.
-
Role of vascular mitogens in subarachnoid hemorrhage-associated cerebral vasculopathy.
-
SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION.
-
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
-
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
-
Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
-
Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
-
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
-
Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation.
-
Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation.
-
Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation.
-
Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
-
Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
-
Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
-
Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells.
-
Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
-
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
-
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
-
Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.
-
Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
-
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Superoxide dismutase mimetic reduces hypoxia-induced O2*-, TGF-beta, and VEGF production by macrophages.
-
Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth.
-
Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues.
-
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
-
Synergy between tumor immunotherapy and antiangiogenic therapy.
-
Synovial fluid metabolites in osteonecrosis.
-
Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.
-
Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization.
-
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
-
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
-
Targeted therapy in rectal cancer.
-
Targeted therapy in renal cell carcinoma.
-
Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
-
Targeting CXCR4-dependent immunosuppressive Ly6Clow
monocytes improves antiangiogenic therapy in colorectal cancer.
-
Targeting Fluorescent Nanodiamonds to Vascular Endothelial Growth Factor Receptors in Tumor.
-
Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
-
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.
-
Targeting the Effect of VEGF in Diabetic Macular Edema.
-
Targeting the future in head and neck cancer.
-
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
-
Technology evaluation: VEGF165 gene therapy, Valentis Inc.
-
Temporal modulation of collective cell behavior controls vascular network topology.
-
Temporal onset of hypoxia and oxidative stress after pulmonary irradiation.
-
The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy.
-
The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology.
-
The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.
-
The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
-
The NLRP3 Inflammasome May Contribute to Pathologic Neovascularization in the Advanced Stages of Diabetic Retinopathy.
-
The Role of Angiogenesis in Hepatocellular Carcinoma.
-
The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.
-
The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer.
-
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
-
The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding.
-
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
-
The effect of cigarette smoke extract on trophoblast cell viability and migration: the role of adrenomedullin.
-
The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching
-
The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.
-
The emerging role of anti-angiogenic therapy for malignant glioma.
-
The fibroblast growth factor receptors, FGFR-1 and FGFR-2, mediate two independent signalling pathways in human retinal pigment epithelial cells.
-
The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype.
-
The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF
-
The promotion of microvasculature formation in poly(ethylene glycol) diacrylate hydrogels by an immobilized VEGF-mimetic peptide.
-
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
-
The role of VEGF in triple-negative breast cancer: where do we go from here?
-
The role of dendritic cell precursors in tumour vasculogenesis.
-
The role of genetics in susceptibility to diabetic retinopathy.
-
The role of targeted therapy in the treatment of colorectal cancer.
-
The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.
-
The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression.
-
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
-
Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF.
-
Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome.
-
Therapy for non-clear cell histologies in renal cancer.
-
Thermal dose fractionation affects tumour physiological response.
-
Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity.
-
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.
-
Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.
-
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.
-
Tissue engraftment of hypoxic-preconditioned adipose-derived stem cells improves flap viability.
-
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
-
Topical VEGF enhances healing of thoracic aortic anastomosis for coarctation in a rabbit model.
-
Topical bevacizumab therapy for corneal neovascularization.
-
Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.
-
Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link?
-
Treatment of age-related macular degeneration.
-
Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
-
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
-
Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.
-
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
-
Trends in age-related macular degeneration management in Singapore.
-
Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney.
-
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
-
Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers.
-
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.
-
Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration.
-
Up-regulation of hypoxia-inducible factor 1 alpha and hemodynamic responses following massive small bowel resection.
-
Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.
-
Use of SMART-generated cDNA for gene expression studies in multiple human tumors.
-
V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.
-
VE-Cadherin Is Required for Cardiac Lymphatic Maintenance and Signaling.
-
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.
-
VEGF as a Paracrine Regulator of Conventional Outflow Facility.
-
VEGF increases retinal vascular ICAM-1 expression in vivo.
-
VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling.
-
VEGF inhibition and renal thrombotic microangiopathy.
-
VEGF inhibition and renal thrombotic microangiopathy.
-
VEGF inhibitors in cancer therapy.
-
VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF
-
VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting.
-
VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases.
-
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
-
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
-
Valvular disease.
-
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
-
Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response.
-
Vascular endothelial growth factor and diabetic complications.
-
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
-
Vascular endothelial growth factor expression in pig latissimus dorsi myocutaneous flaps after ischemia reperfusion injury.
-
Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.
-
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
-
Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.
-
Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
-
Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades.
-
Vascular endothelial growth factor signaling is necessary for expansion of medullary microvessels during postnatal kidney development.
-
Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells.
-
Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer.
-
Vascular interference: a blockade to tumor epithelial growth.
-
Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer.
-
Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis.
-
Vascular-mesenchymal cross-talk through Vegf and Pdgf drives organ patterning.
-
Vascular-targeted photothermal therapy of an orthotopic murine glioma model.
-
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
-
Vegfaa instructs cardiac muscle hyperplasia in adult zebrafish.
-
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
-
Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
-
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
-
Voluntary running prevents progressive memory decline and increases adult hippocampal neurogenesis and growth factor expression after whole-brain irradiation.
-
Ziv-aflibercept: binding to more than VEGF-A--does more matter?
-
[A novel model for visualization of tumor cell-induced angiogenesis in vivo].
-
[Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].
-
p38gamma mitogen-activated protein kinase is a key regulator in skeletal muscle metabolic adaptation in mice.
-
p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene.
-
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
-
Keywords of People
-
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Bowes Rickman, Catherine,
George and Geneva Boguslavsky Distinguished Professor of Eye Research,
Cell Biology
-
Curtis, Lesley H.,
Professor in Population Health Sciences,
Medicine, General Internal Medicine
-
Fekrat, Sharon,
Professor of Ophthalmology,
Ophthalmology, Vitreoretinal Diseases & Surgery
-
McDonnell, Donald Patrick,
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine,
Cell Biology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Mruthyunjaya, Prithvi,
Adjunct Associate Professor in the Department of Ophthalmology,
Ophthalmology, Vitreoretinal Diseases & Surgery
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering